#eli lilly
21 stories
Cramer backs healthcare stocks as markets rotate
Jim Cramer's investing club sees money flowing into healthcare and consumer staples as semiconductor and cybersecurity stocks fall.
CNBC · 1m
GLP-1 drugs show anti-aging effects but side effects remain unclear
Weight-loss drugs reduce biological age markers, but researchers are still discovering unexpected effects on hair, nails, vision and more.
MIT Technology Review · 2m
The risky boom in cut-price weight-loss drugs
Compounding pharmacies are flooding the market with cheaper versions of GLP-1 drugs, but with far less oversight than brand-name alternatives.
TIME · 3m
GLP-1 lawsuits mount as serious harms remain unclear
Thousands of patients are suing GLP-1 drugmakers over blindness and pancreatitis, but weak reporting systems make it hard to know how often the drugs cause real harm.
NPR · 2m
Eli Lilly Price Target Boost
Berenberg upgrades Eli Lilly to Buy with 20% upside potential.
Yahoo Finance · 1m
New weight-loss drugs promise fewer side effects
Amylin-based medications show promise as alternatives to GLP-1 drugs, causing less nausea and stomach trouble while delivering comparable weight loss.
TIME · 2m
Eli Lilly Q2 2026 Revenue Surge
Lilly's Mounjaro revenue nearly doubled to $9.94 billion in Q2 2026, driving 48% revenue growth.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Novo CEO eyes M&A deals as weight-loss dominance slips
Novo Nordisk's turnaround plan failed to convince investors, prompting CEO Mike Doustdar to signal openness to acquisitions beyond obesity drugs.
CNBC · 2m
Eli Lilly's weight-loss drug shows strong results
An experimental drug from Eli Lilly called retatrutide produced significant weight loss in two new studies, outperforming existing medications.
TIME · 2m
Ken Langone's Eli Lilly Stock Bet
Ken Langone predicts Eli Lilly stock hits $2,000 in 3-4 years, surpassing Home Depot's value.
24/7 Wall St. · 1m
Lilly captures 70% of new Medicare GLP-1 patients
Eli Lilly CEO says 700,000 seniors started weight loss drugs after Medicare coverage launched in July, with Lilly drugs taking the majority.
CNBC · 1m
Obesity drug cuts weight by 25 percent in trial
Retatrutide, a triple-acting hormone treatment from Eli Lilly, showed the strongest weight loss results yet in late-stage testing.
Ars Technica · 2m
Eli Lilly's Tough Month: Bank Predicts 37% Gains
Citi forecasts 37% stock gains for Eli Lilly as selloff ends.
24/7 Wall St. · 1m
Lilly claims one-third of new GLP-1 pill patients
Eli Lilly CEO says Foundayo is capturing a third of new oral GLP-1 patients as the company breaks ground on a six point five billion dollar Houston manufacturing facility.
CNBC · 1m
Novo's growth plan fails to impress investors
The Danish drugmaker's strategy to diversify beyond weight-loss drugs disappoints the market as patent expiry looms.
CNBC · 1m
Eli Lilly's $1500 Target Surprises Wall Street
Eli Lilly's revenue growth outpaces stock price, with analysts missing a $1500 target by 2027
24/7 Wall St. · 1m
Nvidia vs. Eli Lilly: Which Stock Wins Next Decade?
Nvidia's AI infrastructure and Eli Lilly's GLP-1 drugs both surged, but which stock has the cleaner path to 10-year growth?
24/7 Wall St. · 1m
Eli Lilly's unapproved weight loss drug sold illegally online
Retatrutide, still in clinical trials, is being marketed and sold to Americans through unauthorized online channels.
CBS News · 1m
How Lilly's AI Chief Built a Drug-Making Supercomputer
Diogo Rau transformed Eli Lilly's approach to medicine by deploying AI and computing power at every stage of drug development.
TIME · 1m
Eli Lilly's obesity bet hinges on September 30 data
A two-drug combo could justify Lilly's trillion-dollar valuation, but the mid-stage trial results will determine if it's a breakthrough or an expensive gamble.
24/7 Wall St. · 1m
Millions still can't afford insulin despite reforms
Despite price caps and policy changes, one in three Americans who need insulin still ration it due to cost.
Vox · 3m